Review of Trial Therapies and Treatment for COVID-19: Lessons for Indonesia
The infectious disease from corona virus, or COVID-19, has quickly spread world-wide since 2019. Therapies for managing COVID-19 have yet to be confirmed as medication for the severe sickness that the disease may cause. This study uses PRISMA guidelines as a method for conducting a systematic literature review. We selected relevant studies published from January 2020 to March 2020 by searching Pubmed, Science Direct and Google Scholar. The research focuses on the treatment of and therapies for COVID-19 only to the patients in the hospital. The inclution 8 articles were screened by using a PRISMA flow after reading 28 abstract and 28 from whole articles. Sixty-seven articles were collected from several online journal databases, and various therapies were found that are effective in the treatment and management of COVID-19. Clinical improvements and Recovery rate have been achieved in a short time compared to standard care only. The findings of the study show that several therapies are effective in managing the severe illness that can be caused by COVID-19. Nevertheless, research into effective therapies for COVID-19 must be continued to find the best therapy and treatment.
1. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924.
2. Kumar V, Jung YS, Liang PH. Anti-SARS Coronavirus agents: A patent review (2008-present). Expert Opin Ther Pat. 2013;23(10):1337–48.
3. Wang L, Wang Y, Ye D, Liu Q. Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence. Int J Antimicrob Agents. 2020;105948.
4. World Health Organization. Coronavirus Disease (COVID-19) Situation Reports. www.who.int. 2020 Jun;
5. Kementrian Kesehatan Indonesia. Situasi Terkini Perkembangan Coronavirus Disease (COVID-19) 3 Juni 2020. www.covid-19.kemkes.go.id. 2020 May;
6. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109(February):102433.
7. Liu C, Zhou Q, Li Y, Garner L V., Watkins SP, Carter LJ, et al. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS Cent Sci. 2020;6(3):315–31.
8. Chan JFW, Yuan S, Kok KH, To KKW, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514–23.
9. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA - J Am Med Assoc. 2020;323(11):1061–9.
10. Chen C, Qi F, Shi K, Li Y, Li J, Chen Y, et al. Thalidomide combined with low-dose glucocorticoid in the treatment of COVID-19 Pneumonia. Preprints. 2020;(February):1–6.
11. Tobaiqy M, Qashqary M, Al-Dahery S, Mujallad A, Hershan AA, Kamal MA, et al. Therapeutic management of patients with COVID-19: a systematic review. Infect Prev Pract. 2020;2(3):100061.
12. Beauchet O, Dubost V, Herrmann FR, Kressig RW. Stride-to-stride variability while backward counting among healthy young adults Dual-taskStride-to-stride variabilityAttentionGait controlHealthy young adults. J Neuroeng Rehabil [Internet]. 2005;2(1):26. Available from: http://www.jneuroengrehab.com/content/2/1/26
13. Tekelab T, Akibu M, Tagesse N, Tilhaun T, Yohanes Y. Neonatal mortality in Ethiopia : a protocol for systematic review and meta-analysis. 2019;1–4.
14. Fakultas Kesehatan Masyarakat Universitas Indonesia. Writing a Protocol (Background and Objective). 2018.
15. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020;1–13.
16.Zhu Z, Lu Z, Xu T, Chen C, Yang G, Zha T, et al. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J Infect. 2020;(xxxx):19–21.
17. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering. 2020;(xxxx):4–10.
18. Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;105949.
19. Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. J Infect. 2020;(xxxx).
20. Chen C, Huang J, Cheng Z, Wu J, Chen S, Zhang Y, et al. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv. 2020;2020.03.17.20037432.
21. Liu K, Chen Y, Wu D, Lin R, Wang Z, Pan L. Effects of progressive muscle relaxation on anxiety and sleep quality in patients with COVID-19. Complement Ther Clin Pract. 2020;39:101132.
22. Asyary A, Veruswati M. Sunlight exposure increased Covid-19 recovery rates: A study in the central pandemic area of Indonesia. Sci Total Environ. 2020;729:139016.
23. Article O. Efficacy of Progressive Muscle Relaxation on Pregnancy Outcome among Anxious Indian Primi Mothers. 2019;0–7.
24. Ferendiuk E, Biegańska JM, Kazana P, Pihut M. Progressive muscle relaxation according to Jacobson in treatment of the patients with temporomandibular joint disorders. 2019;LIX:113–22.
25. Slusky DJG, Zeckhauser RJ. Sunlight and Protection A gainst Influenza. 2018;0–34.
26. World Health Organization. Off-Label Use of Medicines for COVID-19. www.who.int. 2020 Mar;
27. Universitas Indonesia. Tim FIK UI da IPB Temukan Kandidat Pencegahan Virus Corona. www.ui.ac.id; 2020.
- There are currently no refbacks.